Literature DB >> 30422193

Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults: The D-PRESCRIBE Randomized Clinical Trial.

Philippe Martin1, Robyn Tamblyn2, Andrea Benedetti2,3,4,5, Sara Ahmed6, Cara Tannenbaum1,7.   

Abstract

Importance: High rates of inappropriate prescribing persist among older adults in many outpatient settings, increasing the risk of adverse drug events and drug-related hospitalizations. Objective: To compare the effectiveness of a consumer-targeted, pharmacist-led educational intervention vs usual care on discontinuation of inappropriate medication among community-dwelling older adults. Design, Setting, and Participants: A cluster randomized trial (D-PRESCRIBE [Developing Pharmacist-Led Research to Educate and Sensitize Community Residents to the Inappropriate Prescriptions Burden in the Elderly]) that recruited community pharmacies in Quebec, Canada, from February 2014 to September 2017, with follow-up until February 2018, and randomly allocated them to intervention or control groups. Patients included were adults aged 65 years and older who were prescribed 1 of 4 Beers Criteria medications (sedative-hypnotics, first-generation antihistamines, glyburide, or nonsteroidal anti-inflammatory drugs), recruited from 69 community pharmacies. Patients were screened and enrolled before randomization. Interventions: Pharmacists in the intervention group were encouraged to send patients an educational deprescribing brochure in parallel to sending their physicians an evidence-based pharmaceutical opinion to recommend deprescribing. The pharmacists in the control group provided usual care. Randomization occurred at the pharmacy level, with 34 pharmacies randomized to the intervention group (248 patients) and 35 to the control group (241 patients). Patients, physicians, pharmacists, and evaluators were blinded to outcome assessment. Main Outcomes and Measures: Discontinuation of prescriptions for inappropriate medication at 6 months, ascertained by pharmacy medication renewal profiles.
Results: Among 489 patients (mean age, 75 years; 66% women), 437 (89%) completed the trial (219 [88%] in the intervention group vs 218 [91%] in the control group). At 6 months, 106 of 248 patients (43%) in the intervention group no longer filled prescriptions for inappropriate medication compared with 29 of 241 (12%) in the control group (risk difference, 31% [95% CI, 23% to 38%]). In the intervention vs control group, discontinuation of inappropriate medication occurred among 63 of 146 sedative-hypnotic drug users (43.2%) vs 14 of 155 (9.0%), respectively (risk difference, 34% [95% CI, 25% to 43%]); 19 of 62 glyburide users (30.6%) vs 8 of 58 (13.8%), respectively (risk difference, 17% [95% CI, 2% to 31%]); and 19 of 33 nonsteroidal anti-inflammatory drug users (57.6%) vs 5 of 23 (21.7%), respectively (risk difference, 35% [95% CI, 10% to 55%]) (P for interaction = .09). Analysis of the antihistamine drug class was not possible because of the small sample size (n = 12). No adverse events requiring hospitalization were reported, although 29 of 77 patients (38%) who attempted to taper sedative-hypnotics reported withdrawal symptoms. Conclusions and Relevance: Among older adults in Quebec, a pharmacist-led educational intervention compared with usual care resulted in greater discontinuation of prescriptions for inappropriate medication after 6 months. The generalizability of these findings to other settings requires further research. Trial Registration: ClinicalTrials.gov Identifier: NCT02053194.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30422193      PMCID: PMC6248132          DOI: 10.1001/jama.2018.16131

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  32 in total

1.  Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group.

Authors:  F A McAlister; S E Straus; G H Guyatt; R B Haynes
Journal:  JAMA       Date:  2000-06-07       Impact factor: 56.272

2.  American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2015-10-08       Impact factor: 5.562

3.  Comparison of the risk difference, risk ratio and odds ratio scales for quantifying the unadjusted intervention effect in cluster randomized trials.

Authors:  Obioha C Ukoumunne; Andrew B Forbes; John B Carlin; Martin C Gulliford
Journal:  Stat Med       Date:  2008-11-10       Impact factor: 2.373

4.  The expanding scope of pharmacists' practice: implications for physicians.

Authors:  Cara Tannenbaum; Ross T Tsuyuki
Journal:  CMAJ       Date:  2013-08-19       Impact factor: 8.262

5.  Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction.

Authors:  Alice Y Y Cheng
Journal:  Can J Diabetes       Date:  2013-03-26       Impact factor: 4.190

6.  A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy.

Authors:  J T Hanlon; M Weinberger; G P Samsa; K E Schmader; K M Uttech; I K Lewis; P A Cowper; P B Landsman; H J Cohen; J R Feussner
Journal:  Am J Med       Date:  1996-04       Impact factor: 4.965

7.  A prototype for evidence-based pharmaceutical opinions to promote physician-pharmacist communication around deprescribing.

Authors:  Philippe Martin; Cara Tannenbaum
Journal:  Can Pharm J (Ott)       Date:  2018-02-08

8.  A consumer-targeted, pharmacist-led, educational intervention to reduce inappropriate medication use in community older adults (D-PRESCRIBE trial): study protocol for a cluster randomized controlled trial.

Authors:  Philippe Martin; Robyn Tamblyn; Sara Ahmed; Andrea Benedetti; Cara Tannenbaum
Journal:  Trials       Date:  2015-06-10       Impact factor: 2.279

9.  A realist evaluation of patients' decisions to deprescribe in the EMPOWER trial.

Authors:  Philippe Martin; Cara Tannenbaum
Journal:  BMJ Open       Date:  2017-05-04       Impact factor: 2.692

10.  Did the new French pay-for-performance system modify benzodiazepine prescribing practices?

Authors:  Cédric Rat; Gaëlle Penhouet; Aurélie Gaultier; Anicet Chaslerie; Jacques Pivette; Jean Michel Nguyen; Caroline Victorri-Vigneau
Journal:  BMC Health Serv Res       Date:  2014-07-11       Impact factor: 2.655

View more
  74 in total

1.  A pharmacist-led pilot program to facilitate deprescribing in a primary care clinic.

Authors:  Collin M Clark; Susan A LaValley; Ranjit Singh; Esra Mustafa; Scott V Monte; Robert G Wahler
Journal:  J Am Pharm Assoc (2003)       Date:  2019-11-02

Review 2.  Deprescribing for Community-Dwelling Older Adults: a Systematic Review and Meta-analysis.

Authors:  Hanna E Bloomfield; Nancy Greer; Amy M Linsky; Jennifer Bolduc; Todd Naidl; Orly Vardeny; Roderick MacDonald; Lauren McKenzie; Timothy J Wilt
Journal:  J Gen Intern Med       Date:  2020-08-20       Impact factor: 5.128

3.  Availability and readability of patient education materials for deprescribing: An environmental scan.

Authors:  Michael Anthony Fajardo; Kristie Rebecca Weir; Carissa Bonner; Danijela Gnjidic; Jesse Jansen
Journal:  Br J Clin Pharmacol       Date:  2019-05-07       Impact factor: 4.335

4.  Usability and feasibility of consumer-facing technology to reduce unsafe medication use by older adults.

Authors:  Richard J Holden; Noll L Campbell; Ephrem Abebe; Daniel O Clark; Denisha Ferguson; Kunal Bodke; Malaz A Boustani; Christopher M Callahan
Journal:  Res Social Adm Pharm       Date:  2019-02-26

Review 5.  Drug deprescription-withdrawal risk, prevention, and treatment.

Authors:  Madison K Bangert; Gabriel M Aisenberg
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-12-20

6.  Counting the Ways to Count Medications: The Challenges of Defining Pediatric Polypharmacy.

Authors:  Katherine A Auger; Samir S Shah; Matthew M Davis; Patrick W Brady
Journal:  J Hosp Med       Date:  2019-08       Impact factor: 2.960

Review 7.  A systems approach to identifying the challenges of implementing deprescribing in older adults across different health-care settings and countries: a narrative review.

Authors:  Mouna Sawan; Emily Reeve; Justin Turner; Adam Todd; Michael A Steinman; Mirko Petrovic; Danijela Gnjidic
Journal:  Expert Rev Clin Pharmacol       Date:  2020-02-27       Impact factor: 5.045

8.  Deprescribing practices for anticonvulsants after benign seizures secondary to high-dose tranexamic acid in a single, large UK cardiothoracic centre.

Authors:  Zihui Tan; Choo Yen Ng; David Jenkins; Linda Barrow; Kamen Valchanov
Journal:  Eur J Hosp Pharm       Date:  2019-05-04

9.  Physician Perspectives on Deprescribing Cardiovascular Medications for Older Adults.

Authors:  Parag Goyal; Timothy S Anderson; Gwen M Bernacki; Zachary A Marcum; Ariela R Orkaby; Dae Kim; Andrew Zullo; Ashok Krishnaswami; Arlene Weissman; Michael A Steinman; Michael W Rich
Journal:  J Am Geriatr Soc       Date:  2019-09-11       Impact factor: 5.562

10.  Polypharmacy Increases Risk of Dyspnea Among Adults With Serious, Life-Limiting Diseases.

Authors:  Kathleen M Akgün; Supriya Krishnan; Shelli L Feder; Janet Tate; Jean S Kutner; Kristina Crothers
Journal:  Am J Hosp Palliat Care       Date:  2019-09-24       Impact factor: 2.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.